Biotech venture funding on track to be a third lower than 2021

After peaking in 2021, Crunchbase News reports that venture funding for biotech start-ups has slowed in 2022, with investment on pace to come in at least a third lower than last year’s levels.

The slowdown comes amid a broader pullback in global venture funding. Across all sectors, investment hit its highpoint in November and has been going down since then. On the exit front, meanwhile, the pace of venture-backed IPOs has slowed to a crawl.

Biotech funding follows the general pattern. In the U.S., biotech start-ups have raised a total of $16.5 billion so far this year, or about $3.2 billion on average per month. In all of 2021, however, nearly $47 billion went into the space, an average of nearly $4 billion per month.

Click here for the full article.

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to Include the name and contact information (phone and email) for follow-up.